Domestic Drug Manufacturing and Tech Market Insights

This chapter explores an executive order aimed at boosting domestic drug manufacturing by streamlining FDA and EPA processes, while also analyzing Palantir's stock performance ahead of its earnings report. The discussion includes insights into the AI trade, historical tech booms, and OpenAI's restructuring plans, highlighting the balance between innovation and market valuation.